Abstract Details

<< Back to Detailed Agenda

8/23/2022  |   3:30 PM - 4:30 PM   |  Governor General I

CMV Prevention: What's Taking So Darn Long

A brief discussion of how the incremental building of scientific evidence is required for a new vaccine or drug (i.e., preclinical studies, phase 1, 2, 3 trials), the safety/efficacy evidence that is needed before licensure or acceptance, and the time and costs involved. CMV-specific challenges, the increased safety concerns around interventions during pregnancy, the lack of universal CMV screening, and the lack of CMV awareness by women and policymakers.

Presentation:
This presentation has not yet been uploaded.

Handouts:
No handouts have been uploaded.

Session Evaluation


Isabelle Boucoiran (POC-Point of Contact,Primary Presenter), isabelle.boucoiran@umontreal.ca;
Isabelle Boucoiran is a maternofetal medicine and reproductive infectious disease specialist as well as a clinician scientist.

      ASHA DISCLOSURE:

Financial - No relevant financial relationship exists.

Nonfinancial - No relevant nonfinancial relationship exists.


      AAA DISCLOSURE:

Financial - No relevant financial relationship exists.




Karen Fowler (Primary Presenter), karenfowler@uabmc.edu;
Karen B. Fowler, DrPH, is a Professor of Pediatrics (Infectious Diseases) and Epidemiology at the University of Alabama at Birmingham. Her research has primarily focused on studies of maternal and congenital cytomegalovirus infections and the role of congenital CMV infection in sensorineural hearing loss in children.

      ASHA DISCLOSURE:

Financial - No relevant financial relationship exists.

Nonfinancial - No relevant nonfinancial relationship exists.


      AAA DISCLOSURE:

Financial - No relevant financial relationship exists.




Soren Gantt (Co-Presenter), soren.gantt.med@ssss.gouv.qc.ca;
Dr. Gantt is a Pediatric Infectious Diseases specialist, the Director of Clinical Research at CHU Sainte-Justine, and Full Professor in the Departments of Microbiology, Infectious Diseases & Immunology and of Pediatrics at the University of Montreal. Dr. Gantt’s current research focuses primarily on the development of CMV vaccines as well as newborn CMV screening programs.

      ASHA DISCLOSURE:

Financial - Receives Consulting fee, Grants for Consulting, Independent contractor (including contracted research) from Moderna, Merck, GSK, VBI Vaccines, Altona Diagnostics.  

Nonfinancial - No relevant nonfinancial relationship exists.


      AAA DISCLOSURE:

Financial - Receives support from Moderna, Merck, GSK, VBI Vaccines, Altona Diagnostics for Consulting and research funding related to CMV vaccine development.